Mostrar el registro sencillo del ítem
dc.contributor.author
Funes, Santiago
dc.contributor.author
Sampor, Claudia
dc.contributor.author
Villasante, Francisco Eduardo
dc.contributor.author
Fandiño, Adriana Cristina
dc.contributor.author
Manzitti, Julio
dc.contributor.author
Sgroi, Mariana
dc.contributor.author
Neira, Pablo
dc.contributor.author
Peralta, Laura
dc.contributor.author
Lagomarsino, Eduardo
dc.contributor.author
Schaiquevich, Paula Susana
dc.contributor.author
Ceciliano, Alejandro
dc.contributor.author
Chantada, Guillermo Luis
dc.date.available
2020-03-16T19:40:10Z
dc.date.issued
2018-08
dc.identifier.citation
Funes, Santiago; Sampor, Claudia; Villasante, Francisco Eduardo; Fandiño, Adriana Cristina; Manzitti, Julio; et al.; Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina; Wiley-liss, Div John Wiley & Sons Inc; Pediatric Blood & Cancer; 65; 8; 8-2018; 1-7
dc.identifier.issn
1545-5009
dc.identifier.uri
http://hdl.handle.net/11336/99674
dc.description.abstract
Background: The feasibility and results of intraarterial chemotherapy, also termed ophthalmic artery chemosurgery (OAC), for retinoblastoma in less developed countries have seldom been reported. Procedure: A retrospective evaluation of a program of OAC in Argentina from 2010 to 2015. Results: Ninety-seven eyes from 81 patients (61 bilateral) were analyzed. In 35 eyes, OAC was given as primary therapy and in 62 it was used for the treatment of tumors with partial response or those relapsing after systemic chemoreduction with focal therapy or external-beam radiotherapy. Twenty-two primarily treated eyes had group D and 13 groups B/C. A total of 400 procedures were carried out. Chemotherapy used included combinations of melphalan, carboplatin, and topotecan. There was no mortality associated with OAC. Toxicity included fever and neutropenia in five (1.25%), hypotension and bradycardia during anesthesia in two and femoral thrombosis in one, eyelid edema in nine, and neutropenia or thrombocytopenia in 28 cycles. With a median follow-up of 48.7 months (range 12–79), the 3-year probability of event-free survival (pEFS) (enucleation and/or radiotherapy were considered events) was comparable for patients who received first-line therapy and those treated at relapse (0.65 vs. 0.63, P = 0.5). In the former, the pEFS was 0.91 and 0.43 for groups B/C and D, respectively (P = 0.01). Two patients died of extraocular dissemination after refusal of enucleation. Conclusions: OAC was feasible with low toxicity. pEFS improved in all groups compared to the previous experience with systemic chemotherapy reducing the use of radiotherapy. The overall mortality associated with OAC is comparable to our previous experience with systemic chemoreduction.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Wiley-liss, Div John Wiley & Sons Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
CARBOPLATIN
dc.subject
CHEMOREDUCTION
dc.subject
CONSERVATIVE THERAPY
dc.subject
INTRAARTERIAL CHEMOTHERAPY
dc.subject
MELPHALAN
dc.subject
RETINOBLASTOMA
dc.subject
TOPOTECAN
dc.subject.classification
Oncología
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-03-13T13:34:51Z
dc.journal.volume
65
dc.journal.number
8
dc.journal.pagination
1-7
dc.journal.pais
Estados Unidos
dc.journal.ciudad
Hoboken
dc.description.fil
Fil: Funes, Santiago. Hospital Universitario Austral; Argentina
dc.description.fil
Fil: Sampor, Claudia. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
dc.description.fil
Fil: Villasante, Francisco Eduardo. Hospital Universitario Austral; Argentina
dc.description.fil
Fil: Fandiño, Adriana Cristina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
dc.description.fil
Fil: Manzitti, Julio. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
dc.description.fil
Fil: Sgroi, Mariana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
dc.description.fil
Fil: Neira, Pablo. Clinica y Maternidad Suizo Argentina; Argentina
dc.description.fil
Fil: Peralta, Laura. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
dc.description.fil
Fil: Lagomarsino, Eduardo. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
dc.description.fil
Fil: Schaiquevich, Paula Susana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Ceciliano, Alejandro. Hospital Universitario Austral; Argentina
dc.description.fil
Fil: Chantada, Guillermo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Hospital Universitario Austral; Argentina
dc.journal.title
Pediatric Blood & Cancer
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.27086
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/pbc.27086
Archivos asociados